CA125: Megadaltons of novel opportunities

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 505-507

  Dorigo, Oliver ^a   Berek, Jonathan S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

CYTOPLASM; EDITORIAL; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; MOLECULAR MODEL; OVARY CARCINOMA; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; TANDEM REPEAT;

CA-125 ANTIGEN; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 33846911768     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.01.035     Document Type: Editorial

References (11)

1. Bast R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., and Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68 (1981) 1331-1337
2. O'Brien T.J., Beard J.B., Underwood L.J., Dennis R.A., Santin A.D., and York L. The CA125 gene: an extracellular superstructure dominated by repeated sequences. Tumour Biol. 276 (2001) 348-366
3. Yin B.W., and Lloyd K.O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem. 276 (2001) 27371-27375
4. Gubbels J.A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 26 5(1) (2006) 50
5. Patankar M.S., Jing Y., Morrison J.C., Belisle J.A., Lattanzio F.A., Deng Y., et al. Potent suppression of natural killer cell response mediated by ovarian tumor marker CA125. Gynecol. Oncol. 99 (2005) 704-713
6. Hogdall E.V., Christensen L., Kjaer S.K., Blaakaer J., Kjaerbye-Thygesen A., Gayther S., et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From the Danish "MALOVA" Ovarian Cancer Study. Gynecol. Oncol. 104 (2007) 506-513 [this issue]
7. Rosen D.G., Wang L., Atkinson J.M., Yu Y., Lu K.H., Diamandis E.P., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99 (2005) 267-277
8. De la Cuesta R., Maestro M.L., Solana J., Vidart J.A., Escudero M., Iglesias E., et al. Tissue quantification of CA125 in epithelial ovarian cancer. Int. J. Biol. Markers 14 (1999) 106-114
9. Zhang L., Yang N., Conejo-Garcia J.R., Katsaros D., Mohamed-Hadley A., Fracchioli S., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003) 203-213
10. Berek J.S., Taylor P.T., Gordon A., Cunningham M.J., Finkler N., Orr J., et al. Randomized, placebo-controlled study of oregovemab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. 22 (2004) 3507-3516
11. Sabbatini P., Dupont J., Aghajanian C., Derosa F., Poynor E., Anderson S., et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res. 12, 18 (2006) 5503-5510